• Stefan DirnhoferEmail author
Part of the Hematologic Malignancies book series (HEMATOLOGIC)


Bone marrow (BM)-based diagnosis of hematologic disorders, in particular lymphoid and myeloid neoplasms, is complex and requires a multidisciplinary, multivalued, and integrative approach that includes morphologic (cytologic and histologic), cytogenetic, and molecular genetic findings and immunophenotyping (flow cytometry and immunohistochemistry). The morphological assessment is based on both the cytology of a bone marrow smear and the histology of a bone marrow trephine biopsy which complement each other.


  1. 1.
    Hasserjian RP, Head DR. Myelodysplastic syndromes. In: Jaffe E, Arber D, Campo E, Harrys M, Quintanilla-Martinez L, editors. Hematopathology. 2nd ed. Philadelphia: Elsevier; 2017.Google Scholar
  2. 2.
    Valent P, Orazi A, Busche G, et al. Standards and impact of hematopathology in myelodysplastic syndromes (MDS). Oncotarget. 2010;1:483–96.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Lambertenghi-Deliliers G, Orazi A, Luksch R, Annaloro C, Soligo D. Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity. Br J Haematol. 1991;78:161–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Fu B, Jaso JM, Sargent RL, et al. Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems. Mod Pathol. 2013;27:681–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Saft L, Karimi M, Ghaderi M, Matolcsy A, Mufti GJ, Kulasekararaj A, Göhring G, Giagounidis A, Selleslag D, Muus P, Sanz G, Mittelman M, Bowen D, Porwit A, Fu T, Backstrom J, Fenaux P, MacBeth KJ, Hellström-Lindberg E. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). Haematologica. 2014;99(6):1041–9.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Buesche G, Teoman H, Wilczak W, Ganser A, Hecker H, Wilkens L, Göhring G, Schlegelberger B, Bock O, Georgii A, Kreipe H. Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia. 2008;22(2):313–22.CrossRefPubMedGoogle Scholar
  7. 7.
    Della Porta MG, Malcovati L, Boveri E, Travaglino E, Pietra D, Pascutto C, Passamonti F, Invernizzi R, Castello A, Magrini U, Lazzarino M, Cazzola M. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol. 2009;27(5):754–62.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.PathologyUniversity Hospital BaselBaselSwitzerland

Personalised recommendations